BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut Allergy Vaccine

ANN ARBOR, Mich., (October 1, 2019) – BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced it has been awarded a Fast-Track Small Business Research Innovation (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of an intranasal therapeutic peanut allergy vaccine using the company’s NanoVax® platform. Pending approval of all phases,Continue reading “BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut Allergy Vaccine”

After Daughter’s Fatal Reaction to Toothpaste, Mother Calls for Caution

Warning: This article contains information that is not suitable for children. Article updated April 19, 2019. A California family has been left devastated after their dairy-allergic daughter and sister died of a severe allergic reaction. Denise Saldate, 11, suffered a fast-moving anaphylactic reaction to milk protein from an unexpected source: a new prescription toothpaste. “She wasContinue reading “After Daughter’s Fatal Reaction to Toothpaste, Mother Calls for Caution”

First Oral Immunotherapy for Peanut Allergy Gets Closer to FDA Vote

A clinical trial for peanut allergy treatment has hit another milestone, with research suggesting graduated doses of peanut protein powder could help protect allergic children. After learning their son Andrew had a serious peanut allergy, Jennifer and Daniel Ayala did everything they could to protect him, from becoming master label readers to sending him toContinue reading “First Oral Immunotherapy for Peanut Allergy Gets Closer to FDA Vote”